Rhumbline Advisers Genfit S.A. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Genfit S.A. stock. As of the latest transaction made, Rhumbline Advisers holds 5 shares of GNFT stock, worth $18. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5
Previous 678
99.26%
Holding current value
$18
Previous $2,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding GNFT
# of Institutions
8Shares Held
54.9KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY27.4KShares$103,9210.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il18.8KShares$71,1110.0% of portfolio
-
Optiver Holding B.V. Amsterdam, P74.64KShares$17,5810.0% of portfolio
-
Ubs Group Ag4.08KShares$15,4660.0% of portfolio
-
Principal Securities, Inc. Des Moines, IA24Shares$900.0% of portfolio
About Genfit S.A.
- Ticker GNFT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,815,500
- Market Cap $189M
- Description
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...